Skip to content

    Recently Viewed

      Listening...

      Home / Latest news /
      Acuvue Oasys® with Transitions™ Light Intelligent Technology™ contact lenses named one of Time’s Best Inventions of 2018
      Eyes showing how contact lenses respond to changing light conditions via a photochromic filter

      Acuvue Oasys® with Transitions™ Light Intelligent Technology™ contact lenses named one of Time’s Best Inventions of 2018

      This first-of-its-kind innovation has a dynamic photochromic filter that responds to changing light conditions.

      Share Article
      share to

      Picture this: You pop in your contact lenses before heading outside on a sunny day and don’t immediately squint—because your lenses have automatically darkened to filter out the bright light, seamlessly keeping your eyes comfortable and your vision crisp.

      Sounds futuristic, right?

      Not anymore, with the development of Acuvue Oasys® with Transitions™ Light Intelligent Technology™. And while the product won’t be available until the first half of 2019, it’s already causing a stir: The contact lenses were just chosen as one of Time‘s Best Inventions of 2018.

      Better sight through Light Intelligent Technology

      Inset- Acuvue Oasys News Item- Acuvue Oasys Contact lens

      A photochromic filter allows the lens to respond to changes in light and darken accordingly (shown left to right)

      Each year, Time seeks out lifestyle innovations that carry the promise of making the world, in their words, “better, smarter and even a bit more fun.” You can check out last year’s winners here.

      The revolutionary Acuvue Oasys with Transitions Light Intelligent Technology lenses experience fits the bill, thanks to a dynamic photochromic filter that responds to changing light conditions—indoors and out—by reducing exposure to bright light, filtering out blue light, blocking UV rays and, of course, providing vision correction at the same time. (Learn more about Acuvue, including safety information.)

      We believe it will redefine how people think about wearing contact lenses, and we are excited to see the world react to this first-of-its-kind innovation.
      Ashley McEvoy

      It’s the brainchild of a partnership between Johnson & Johnson Vision Care, Inc. and Transitions Optical—the leading provider of photochromic smart adaptive eyeglass lenses worldwide. In April of this year, the lenses were cleared by the U.S. Food and Drug Administration (FDA) as the first to be invented with light adaptive technology.

      “The introduction of Acuvue Oasys with Transitions Light Intelligent Technology has been 15-plus years in the making, and its distinction as a Time Best Invention of 2018 is incredibly meaningful to the many researchers, scientists, engineers and others who have seen the product from its initial concept,” says Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, Johnson & Johnson. “We believe it will redefine how people think about wearing contact lenses, and we are excited to see the world react to this first-of-its-kind innovation.”

      Considering getting contacts?

      Check out this new wearer guide, packed with great tips for safely and comfortably using contact lenses.

      More from Johnson & Johnson

      Innovation
      Headshots of three Johnson and Johnson female scientists

      Meet 3 leaders who are breaking new ground for women in healthcare

      For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
      Innovation
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      Innovation
      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.